Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Spero Therapeutics (SPRO) Q2 2026 Earnings Call Transcript

CEO Rajavelu discusses $105 million financing and SP001 immunology strategy.

We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.

Also reported by 1 other outlet

Read the original at fool.com →

More in Finance & Markets

More from Wednesday 19 August →